Related Experiment Videos
Does a low sodium diet modify heart rate variability? A randomised placebo-controlled double-blind trial
International Journal of Cardiology
|December 9, 2008
Summary
A low sodium diet did not significantly change heart rate variability (HRV) over six weeks in asthma patients. Further research is needed with greater dietary sodium reduction and longer study durations.
Area of Science:
- Cardiology
- Nutritional Science
- Respiratory Medicine
Background:
- Increased heart rate variability (HRV) is linked to lower mortality risk.
- Low sodium diets are also associated with improved survival rates.
- The study explored if low sodium diets could enhance HRV, potentially mediating survival benefits.
Purpose of the Study:
- To test the hypothesis that adopting a low sodium diet increases heart rate variability (HRV).
Main Methods:
- A randomized, double-blind, placebo-controlled trial was conducted.
- Participants with asthma (aged 18-65) were assigned to a low sodium diet.
- Groups received either 80 mmol/day sodium supplements (normal sodium intake - NSI) or placebo (low sodium intake - LSI) for 6 weeks.
- Primary outcome: change in SDNN (standard deviation of the N-N intervals).
Main Results:
- Low sodium intake (LSI) reduced daily urinary sodium excretion by 22 mmol.
- Normal sodium intake (NSI) increased daily urinary sodium excretion by 31 mmol.
- No significant differences in SDNN or other HRV measures were observed between LSI and NSI groups.
Conclusions:
- A low sodium diet does not impact SDNN over a 6-week period.
- Future studies require larger dietary sodium changes and longer durations to assess HRV impact.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:28Mitral Regurgitation IV: Nursing Management
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...